Fig. 5.

Sensitivity to a Src/ABL kinase inhibitor demonstrates overlap with erlotinib sensitivity and EGFR mutation status. Pie chart representation of the sensitivity of 500 human cancer cell lines to treatment with 2 μM Src/ABL kinase inhibitor AZD0530. The drug effect was calculated as the fraction of untreated cells present after 72 h of treatment. The most sensitive cell lines are detailed in the chart together with their sensitivity to a similar duration of treatment with 200 nM EGFR inhibitor erlotinib, including their EGFR kinase domain mutation status where known.